Decentralized clinical trials (DCTs) have increased in popularity in recent years, expanding options for participation. What trends have influenced this shift, and how can the industry best implement decentralized elements to drive advancements in clinical research and patient experience? This white paper explores these topics, starting with a look at the history of DCTs and an eye toward the future of decentralization.
Download your copy to explore:
- Features of early DCTs/hybrid trials and corresponding FDA regulations
- How the COVID-19 pandemic resulted in a surge of decentralization
- The current state of remote and hybrid trials
- Factors that influence the feasibility and benefits of research decentralization
- Considerations for ethics and compliance in decentralized and hybrid clinical trials